GUJTHEM

Gujarat Themis Biosyn share price & financials

Price
₹383.55
Market cap
₹3.8k Cr
Sector
Healthcare
Calls analysed
6
Latest concall · Q1 FY27 · call held 10 Aug 2026

Gujarat Themis Biosyn Limited Q1 FY27

Revenue from Operations ₹43.8 cr +22%EBITDA ₹20.8 cr +49%EBITDA Margin 47.5% PAT ₹11.1 cr +22%

What went well

  • Revenue from operations grew 22.1% YoY to INR 43.8 crores, reflecting healthy demand.
  • EBITDA grew 49.4% YoY to INR 20.8 crores, with EBITDA margin expanding by 867 basis points to 47.5%.
  • Profit after tax grew 22.1% YoY to INR 11.1 crores.

What to watch

  • API block revenue realization was delayed by 2 years compared to earlier guidance for FY25, attributed to fermentation capacity constraints.
  • Promoter share pledge reduction, while initiated with 2% released, still requires significant reduction over the next 12-15 months.
Read the full call →

What Gujarat Themis Biosyn Limited does

Gujarat Themis Biosyn Limited manufactures fermentation-based pharmaceutical intermediates (Rifamycin-S and Rifamycin-O) and Active Pharmaceutical Ingredients used in anti-tuberculosis and anti-infective drug formulations, selling in bulk to domestic and international pharmaceutical formulators, often through tender-driven orders. It operates from a single fermentation-and-synthesis-based plant in Vapi, Gujarat, and is forward-integrating into API manufacturing and new molecule R&D to serve regulated export markets such as the US and Europe. The company is part of the Themis group of companies (co-located with promoter Themis Medicare Limited) and has no subsidiaries, associates or joint ventures of its own. In April 2026 it signed an agreement to acquire Sanofi's global anti-TB and anti-infective branded generics portfolio, an asset-light deal intended to give it direct access to international markets, pending antitrust and FDI approvals.

Manufacturing facility
Single fermentation- and synthesis-based API/intermediates plant, Vapi (GIDC), Gujarat
Dedicated API block
New forward-integration API manufacturing block completed; validation batches underway
R&D facility
Phase 1 of new fermentation-led R&D facility commissioned
Target export markets
United States and Europe (regulated markets)
Corporate structure
No subsidiaries, associate or joint venture companies (standalone entity)
Group affiliation
Part of the Themis group; shares registered-office campus with promoter Themis Medicare Limited
Founded 1981Headquarters Vapi, Gujarat, India Company website

Guidance record · Q1 FY27

what the last two calls moved 14 tracked 3 delivered 5 missed 6 open
  • Total CAPEX Plan delivered, diluted said Q2 FY22 Promised: ₹200-plus crores over next 2-3 years Q1 FY27: Confirmed ~₹370 crores invested over the last 3 years, largely completing the capex cycle. This exceeds the original ₹200cr target but is below the revised 'at least double' (₹400cr+) guidance, and was completed late.
  • API Block Commissioning missed said Q2 FY23 Promised: End of Q2 FY2024 (Sept 2023) Q1 FY27: Acknowledged significant delay; API block has 'just begun now' due to fermentation capacity constraints, missing the Dec 2023 target by ~2.5 years.
  • Revenue Growth open said Q1 FY27 Promised: high-teen basis Q1 FY27: Guided for top-line growth on a 'high-teen basis' on a base case.

All 14 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 22.2%, net profit up 22.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue35 40 38 36 42 +20%43 +8%44 +16%44 +22%
EBITDA15 19 16 14 21 +40%21 +11%19 +19%21 +50%
Net profit11 13 12 9 14 +27%12 −8%11 −8%11 +22%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +11.4% 1Y

₹250₹300₹350₹400₹450Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q1 FY27 — 10 Aug 2026

1Y: ₹379.25 on 10 Sept 2025 → ₹422.65. High ₹469.9 (27 Oct 2025), low ₹226.9 (30 Mar 2026).

How the price took the results

close before → close after

Q1 FY27
+3.3%
10 Aug

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 3.5% a year over 3 years, FY23 to FY26. Operating margin narrowed to 45.5%.

Year endingFY23FY24FY25FY26
Revenue₹149 Cr₹171 Cr₹152 Cr₹165 Cr
Operating profit₹73 Cr₹80 Cr₹69 Cr₹75 Cr
Operating margin48.9%46.8%45.4%45.5%
Interest₹0 Cr₹0 Cr₹0 Cr₹3 Cr
Depreciation₹4 Cr₹4 Cr₹5 Cr₹13 Cr
Net profit₹59 Cr₹60 Cr₹49 Cr₹46 Cr
Net margin39.5%35.1%32.2%27.9%
Cash from operations₹39 Cr₹64 Cr₹91 Cr₹49 Cr
Free cash flow₹16 Cr₹-10 Cr₹-25 Cr₹-124 Cr
ROCE61.0%45.0%27.0%18.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹7 Cr₹7 Cr₹7 Cr₹7 Cr₹11 Cr₹11 Cr
Reserves₹63 Cr₹96 Cr₹142 Cr₹194 Cr₹254 Cr₹277 Cr
Borrowings₹5 Cr₹1 Cr₹0 Cr₹3 Cr₹71 Cr₹162 Cr
Other liabilities₹14 Cr₹18 Cr₹17 Cr₹17 Cr₹41 Cr₹54 Cr
Total liabilities₹88 Cr₹122 Cr₹166 Cr₹221 Cr₹377 Cr₹503 Cr
Fixed assets₹19 Cr₹19 Cr₹33 Cr₹38 Cr₹162 Cr₹289 Cr
Capital work in progress₹2 Cr₹13 Cr₹21 Cr₹91 Cr₹132 Cr₹121 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹67 Cr₹90 Cr₹113 Cr₹92 Cr₹82 Cr₹93 Cr
Total assets₹88 Cr₹122 Cr₹166 Cr₹221 Cr₹377 Cr₹503 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, FIIs trimmed −0.75 pp while the public added +0.74 pp. The shareholder count shrank 7% to 27,010.

Promoters
70.9%
FIIs
1.8%
DIIs
1.2%
Public
26.2%

Since Jun 2025

  • FIIs −0.75 pp
  • Public +0.74 pp
  • Promoters 0.00 pp

How it drifted, 12 quarters

Over this window promoters fell from 75.0% to 70.9% — −4.1 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 75.0%, FIIs 0.0%, DIIs 0.0%, Public 25.0%.Dec '23: Promoters 70.9%, FIIs 0.9%, DIIs 0.0%, Public 28.2%.Mar '24: Promoters 70.9%, FIIs 1.1%, DIIs 0.8%, Public 27.3%.Jun '24: Promoters 70.9%, FIIs 1.4%, DIIs 1.2%, Public 26.5%.Sep '24: Promoters 70.9%, FIIs 1.5%, DIIs 1.2%, Public 26.5%.Dec '24: Promoters 70.9%, FIIs 1.4%, DIIs 1.2%, Public 26.6%.Mar '25: Promoters 70.9%, FIIs 1.9%, DIIs 1.2%, Public 26.1%.Jun '25: Promoters 70.9%, FIIs 2.5%, DIIs 1.2%, Public 25.4%.Sep '25: Promoters 70.9%, FIIs 3.0%, DIIs 1.2%, Public 25.0%.Dec '25: Promoters 70.9%, FIIs 2.0%, DIIs 1.2%, Public 26.0%.Mar '26: Promoters 70.9%, FIIs 1.8%, DIIs 1.2%, Public 26.1%.Jun '26: Promoters 70.9%, FIIs 1.8%, DIIs 1.2%, Public 26.2%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Gujarat Themis Biosyn Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Pharmaceutical Business Group [India] Ltd 47.02%unchanged
Themis Medicare Limited 20.90%−2.29 pp
Sachin Dinesh Patel 2.29%+2.29 pp
Quant Mutual Fund - Quant Manufacturing Fund Mutual fund1.15%unchanged
Ayushmat Ltd FPI fund1.12%unchanged
Dinesh Shantilal Patel, Jayshree Dinesh Patel, Sachin Dinesh Patel (Trustees of Vividhmargi Trust) 0.61%newly disclosed
Nysha Rupen Choksi 0.02%unchanged
Anay Rupen Choksi 0.02%unchanged
Jayshree D Patel 0.00%unchanged
OSS Software Solutions Labs Private Limited 0.00%newly disclosed
Dinesh Shantilal Patel 0.00%unchanged
Reena S Patel 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

All earnings calls (6)

Read the Q1 FY27 call →

Learn to analyse Gujarat Themis Biosyn Limited

Guides on how to read this kind of business and the numbers that matter.